公司概覽
業務類別 Biotechnology
業務概覽 Achieve Life Sciences Inc is a late-stage specialty pharmaceutical company focused on the world-wide development and commercialization of cytisinicline as a treatment for nicotine dependence. Its New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two completed Phase 3 studies and an open-label long-term safety study. It has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.
公司地址 22722 29th Drive SE, Suite 100, Bothell, WA, USA, 98021
電話號碼 +1 604 210-2217
傳真號碼 --
公司網頁 https://www.achievelifesciences.com
員工數量 28
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Cindy Jacobs,PhD,M.D. Director, President and Chief Medical Officer 美元 484.67K 11/09/2025
Dr. Anthony Clarke,PhD Chief Scientific Officer -- 21/04/2022
Mr. John Bencich Director, Principal Financial Officer and Chief Executive Officer 美元 530.00K 26/04/2024
Mr. Mark K. Oki Chief Financial Officer -- 08/06/2026
Mr. Jerry Wan Principal Accounting Officer and Vice President, Finance -- 24/03/2026
Dr. Andrew Goldberg, M.D. Chief Executive Officer, President and Director -- 16/04/2026
Mr. Erik Atkisson Chief Legal Officer 美元 130.26K 08/06/2026
Mr. Benjamin Halladay Chief Financial Officer -- 01/10/2026
Ms. Jaime Xinos Chief Commercial Officer -- 12/05/2026
Mr. Craig Donnelly Chief Operations Officer -- 08/06/2026
Mr. Mark Lawrence Rubinstein Chief Medical Officer -- 08/06/2026
Mr. Ronald Dadino Senior Vice President, Chemistry, Manufacturing and Controls and Supply Chain -- 03/08/2026
Ms. Gloria Cosgrove Senior Vice President, Quality -- 03/08/2026
 
董事會成員
董事會 職務 更新日期
Dr. Cindy Jacobs,PhD,M.D. Director, President and Chief Medical Officer 11/09/2025
Mr. Donald R. Joseph Lead Independent Director 30/03/2023
Mr. Jeffrey S. Farrow Independent Director 08/06/2026
Dr. Martin A. Mattingly,Pharm.D. Independent Director 30/03/2023
Mr. Thomas Braxton King Interim Executive Chairman of the Board 12/05/2026
Mr. Jay M. Moyes Independent Director 30/03/2023
Dr. Vaughn B. Himes,PhD Independent Director 26/04/2024
Mr. John Bencich Director, Principal Financial Officer and Chief Executive Officer 26/04/2024
Mr. Richard Alistair Balfour Stewart Director 16/04/2026
Dr. Bridget A. Martell, M.D. Independent Director 08/06/2026
Dr. Aaron Royston, M.D. Independent Director 12/05/2026
Ms. Kristen B. Slaoui, PhD Director 10/01/2025
Dr. Andrew Goldberg, M.D. Chief Executive Officer, President and Director 16/04/2026
Dr. Lucian Iancovici, M.D. Chairman of the Board 12/05/2026
Mr. Thomas Sellig Independent Director 08/06/2026
Mr. Stuart M. Duty Independent Director 08/06/2026
Mr. Tom Sellig Director 30/03/2023
Ms. Nancy R. Phelan Independent Director 08/06/2026
Dr. Kristin Slaoui, PhD Independent Director 08/06/2026
Mr. Christopher Martin Director 12/05/2026
Mr. Jeffery Farrow Director 02/06/2026
Dr. Reid Waldman, M.D. Director 02/06/2026
Mr. Chris Martin Independent Director 08/06/2026
 
所屬ETF (更新日期: 10/11/2026 07:30)
代號 名稱 佔比% ▼ 持有日期
HDGProShares Hedge Replication0.0001%30/09/2026
RBProshares Russell 2000 Dynamic BufferETF0.00003%30/09/2026
AVTMAvantis Total Equity Markets ETF<0.000001%24/07/2026
DFASDimensional US Small Cap ETF<0.000001%01/07/2021
DFSUDimensional US Sustainability Core 1 ETF<0.000001%28/11/2023
IWNiShares Russell 2000 Value ETF<0.000001%27/06/2025
MSSMMorgan Stanley Pathway Sm-Md Cp Eq ETF<0.000001%30/06/2025
VTWVVanguard Russell 2000 Value ETF<0.000001%30/06/2025
  1   2  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.